Overview

* Akebia Q3 2025 total revenue grows to $58.8 mln, driven by Vafseo and Auryxia sales

* Net income for Q3 2025 beats analyst expectations, marking a turnaround from last year

* Company expects Vafseo patient access to grow to 275,000 by year-end

Outlook

* Akebia expects Vafseo prescribing access to reach 275,000 patients by year-end

* Company anticipates DaVita pilot completion in Q4, expanding Vafseo availability

* Akebia will not pursue broad label for Vafseo in non-dialysis CKD patients

Result Drivers

* VAFSEO SALES - Q3 2025 net product revenue for Vafseo reached $14.3 mln, primarily from US Renal Care

* FAVORABLE OUTCOMES - Post-hoc data analysis shows Vafseo has more favorable outcomes in mortality and hospitalization compared to ESAs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.03

(5

Analysts

)

Q3 Net Beat $540,000 -$8.43

Income mln (5

Analysts

)

Q3 Beat $4.45 $3.08

Operatin mln mln (5

g Income Analysts

)

Q3 Basic

EPS

Q3 $44.93

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Akebia Therapeutics Inc ( AKBA ) is $6.00, about 66% above its November 7 closing price of $2.04

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 109 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)